iPower Registers 27.1M Shares for Resale Under $22.4M Convertible Note Facility, Adds $2M Tranche

summarizeSummary

iPower registers 27.1 million shares for resale under a $22.4 million convertible note facility, adding a new $2 million tranche and removing use-of-proceeds restrictions. The potential dilution is extreme—outstanding shares could increase 15-fold—with conversion prices as low as $0.40, far below the current $1.53 stock price.

check_boxKey Events · Financing and Capital Events · IPW

• Registers 27.1M Shares for Resale

  The S-1 registers 27,135,484 shares underlying $22.4 million of Series A convertible notes, including a new $2 million tranche issued July 6, 2026. This is in addition to prior registrations and reflects the full remaining facility.

• Extreme Potential Dilution

  With only 1,891,147 shares outstanding, full conversion would increase the share count to 29,026,631—a 15-fold increase. Conversion prices are as low as $0.40 (floor) or $1.55 (alternate), both below the current $1.53 stock price.

• Use of Proceeds Shift

  The company removed prior restrictions on use of proceeds and now intends to use funds from additional note sales to pay off existing loans, invest in digital assets, and for general corporate purposes.

• Financial Distress Context

  This filing follows a catastrophic Q3 (revenue down 78%, net loss of $3.5M) and a going-concern risk. The company is relying on highly dilutive convertible notes to fund operations and its new digital asset strategy.

auto_awesomeAnalysis · IPW · Trade & Services

iPower is registering 27.1 million shares for resale by an institutional investor, covering conversion of $22.4 million in Series A convertible notes. This includes a new $2 million tranche issued July 6, 2026, and removes prior restrictions on use of proceeds, now earmarked for debt repayment, digital asset purchases, and general corporate purposes. With only 1.89 million shares outstanding, the potential dilution is extreme—if all registered shares were issued, the share count would balloon to over 29 million. The notes convert at a floor price of $0.40 or an alternate price of $1.55 (95% of the lowest VWAP), both well below the current $1.53 stock price, creating significant overhang. This filing comes amid severe financial distress: a catastrophic Q3 with revenue down 78%, a net loss of $3.5 million, and a going-concern risk. The company is using this toxic financing to stay afloat, but the cost is massive dilution for existing shareholders.